Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. - Wikidata - awgldk - TriplyDB

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

http://www.wikidata.org/entity/Q34611373

about

New and emerging disease modifying therapies for multiple sclerosis Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases Current and emerging therapies in multiple sclerosis: a systematic review Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1 K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action via antioxidative pathway activation Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway Regulation of dimethyl-fumarate toxicity by proteasome inhibitors Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display.What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Current and future therapies for multiple sclerosis.Fumarate modulates the immune/inflammatory response and rescues nerve cells and neurological function after stroke in rats.Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors.Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.Treatment of multiple sclerosis: current concepts and future perspectives.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.The benefits and detriments of macrophages/microglia in models of multiple sclerosis Mechanisms of white matter damage in multiple sclerosis.The glutathione system: a new drug target in neuroimmune disorders.Dimethyl fumarate for treating relapsing multiple sclerosis.Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.Multiple Sclerosis: Immunopathology and Treatment Update.Potential antianxiety activity of Fumaria indica: A preclinical study.Regulation of proton-coupled folate transporter in retinal Müller cells by the antipsoriatic drug monomethylfumarate.Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation.Role of fumaric acid in anti-inflammatory and analgesic activities of a Fumaria indica extracts.Majoon ushba, a polyherbal compound, suppresses pro-inflammatory mediators and RANKL expression via modulating NFкB and MAPKs signaling pathways in fibroblast-like synoviocytes from adjuvant-induced arthritic rats.Limits in Proton Nuclear Singlet-State Lifetimes Measured with para-Hydrogen-Induced Polarization.Therapeutic effects of oral dimethyl fumarate on stroke induced by middle cerebral artery occlusion: An animal experimental study.

P2860

Q22242305-947B6B46-0177-4D99-93EF-585003D7B432 Q26752859-FE644207-C089-40F6-AF75-AF9FECF1458D Q26823444-BDE7C211-6A80-47D6-9E7D-834485CA4B9F Q28078742-B513BE04-CBBD-448D-863E-82024C92B0AF Q29010983-F982B66A-8F23-4A8D-BCC1-A227573672E7 Q30699740-4DCD29BD-171B-4EA5-B931-D90DDC86A562 Q33621682-9641EF3A-8CC2-4093-AA23-330465BF6321 Q33755345-51FEDE38-D7DF-4581-B91C-495C0A645F2C Q34441024-38E9EB97-201E-4C15-9577-7D2A3CA9613C Q34556462-D2E3F289-F153-4FE9-A6F3-1C0DCBD8F726 Q34667496-5B36E03A-FEC2-44FA-BF3B-E0450F4E6AA7 Q34773115-0DDB9EF0-5CE8-478F-A78B-0DE9230F113C Q34990563-77540A1C-DF33-4A8E-8E98-AF7F488C90A2 Q35814106-3BE62EAA-FDB4-4B9C-8DCE-5E345972F3B2 Q36215658-9BC8377A-0E0E-4DC5-8433-972923C18007 Q36368828-13A54789-135B-44B3-BFB1-C2DCB8AD1B68 Q36396476-43A6AC19-4ABB-4FEC-86AB-431F1214F1FA Q37287769-E31211B8-9042-4DEE-8DDF-50F34E461A69 Q37336648-B357DAA1-971B-468E-9E71-9A9A39D63E5A Q37446412-8B8BC9B8-96DB-4027-86B7-4A232E5C4A02 Q37720346-37432E75-971D-4D70-B854-585C692319B6 Q37884434-C19D5B42-372A-4234-8DE0-C9F28E1FB2B0 Q38117110-D388FA37-9879-4FAF-B7BF-791C720C31CA Q38120527-66F0786E-B0A8-45F5-9327-C798E63859D6 Q38182524-086F16F2-F9E4-4409-9036-2C26EC4A016E Q38206126-EFC0B37B-6A99-4144-B785-4609F938BAF6 Q38266397-C031CC3B-CFC8-4CE3-9E46-022E81CAA449 Q39100528-B02D3786-C71A-4260-A771-CDE8C12C2AD3 Q39420793-D8382604-F348-4307-A6B7-1599336A77DD Q40503029-80243DC2-EE17-4169-883B-C2CB0DA19BD1 Q40642015-4AF19EE0-52B7-4B45-8FF1-9CF3448B2EF2 Q42174998-E0B366BB-0942-4144-97F7-D79B3AD2D467 Q42265071-DAE09761-999E-4124-8A8B-0528B90E7724 Q50862393-051DE03D-8A42-4861-B304-9A7860D1BCA6 Q51230589-85B4620A-0729-4D01-9B73-E83769BD657D Q52095014-12AD2C24-5687-433B-9C48-7CDA836A05CD

P2860

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

http://www.wikidata.org/entity/Q34611373

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@ast

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@en

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@nl

type

label

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@ast

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@en

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@nl

prefLabel

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@ast

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@en

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@nl

P1433

Q34611373-68B3D67F-70D8-4E20-96FA-A969F47EBDC6

P1476

Q34611373-E9DC8B7A-6DAD-4930-BA9E-680CB4823569

P2093

Q34611373-619A140B-71FA-4921-8388-AB542638291A

Q34611373-77303F25-4D34-4A6E-BF7D-9145FAB79274

Q34611373-980B0387-DDF7-483F-8390-877CB71D9967

Q34611373-C81F54FE-612F-4A14-855D-479ACB2573CF

P2860

Q34611373-06ECB3DF-18DC-4243-B035-1B90975EDC50

Q34611373-0C70C49A-2EDB-4686-B832-2221378F6AF2

Q34611373-149D19DA-8BA1-4000-A267-BF91D23B6210

Q34611373-15C7CF6B-F500-426C-BAB7-3455FAF71F32

Q34611373-16DEB853-BAAB-40DF-A083-C06F8B2A3188

Q34611373-2267D140-698A-4BF1-B304-BE1DB5986913

Q34611373-2F11D42B-D9E5-44BB-A5EF-1671FDD3D2C7

Q34611373-30082270-3D90-419E-9B6A-BD5BB91137B9

Q34611373-613FBCD3-608C-46F3-AB81-832B1DEE010A

Q34611373-7ABE59D2-666A-4A47-82B6-1B87FDC7E117

P304

Q34611373-1E31F3CC-7B2D-4221-A667-F78A99364DC4

P31

Q34611373-E6106CF9-431F-49B3-9FF5-226775B29234

P356

Q34611373-7C1EE19D-0848-4EBA-B3F6-08F4AF087D79

P433

Q34611373-0FD95E7E-2971-46A7-9E4A-79BF2C6BFD29

P478

Q34611373-4AD4009E-5589-4DC0-98C9-D4C1E27765D4

P577

Q34611373-36ECEF42-321A-40A6-A8CF-11F6A4AB6879

P5875

Q34611373-DFB07919-DF98-4609-B322-CA5CAEA5F181

P698

Q34611373-1B1BCA33-B2B2-4E1F-9AB6-D7F11CF32E47

P921

Q34611373-4FE02283-A435-45CB-8F4C-E801E12B7087

P932

Q34611373-5AD21C3B-24F9-4EEB-AFD8-693C0931B2DE

P356

157015909787602788

P1433

Current Neuropharmacology

P1476

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

@en

P2093

D Moharregh-Khiabani

http://www.w3.org/2001/XMLSchema#string

M Stangel

http://www.w3.org/2001/XMLSchema#string

R A Linker

http://www.w3.org/2001/XMLSchema#string

R Gold

http://www.w3.org/2001/XMLSchema#string

P2860

The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells

Inhibition of dendritic cell differentiation by fumaric acid esters.

Dimethylfumarate for psoriasis: more than a dietary curiosity.

Treatment of psoriasis with fumaric acid esters (Fumaderm).

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate.

Pharmacokinetics of oral fumarates in healthy subjects.

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

Drug evaluation: BG-12, an immunomodulatory dimethylfumarate.

The antipsoriatic dimethyl-fumarate suppresses interferon-gamma -induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique.

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.

P304

60-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/157015909787602788

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26781446

http://www.w3.org/2001/XMLSchema#string

P698

19721818

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

2724664

http://www.w3.org/2001/XMLSchema#string